Michael Cilento

Adelaide Medical School

Faculty of Health and Medical Sciences

Dr Michael Cilento MBBS FRACP is a medical oncologist and PhD candidate in the Prostate Cancer Research Group at the South Australian Health and Medical Research Institute (SAHMRI) led by Professor Lisa Butler. Dr Cilento received his medical degree from the University of Adelaide and did his residency at the Royal Adelaide Hospital. He completed his oncology training in South Australia, which was followed by a fellowship in early drug development and phase 1 clinical trials at the Peter MacCallum Cancer Centre Melbourne. Dr Cilento joined Flinders Centre for Innovation in Cancer in 2024. He then returned to the Royal Adelaide Hospital as a consultant medical oncologist in 2025. Dr Cilento's PhD research is utilising spatial profiling methods to identify novel metabolic drivers of lethal prostate cancer.

Publications
Contact

Journals

Year	Citation
2024	Cilento, M. A., Sweeney, C. J., & Butler, L. M. (2024). Spatial transcriptomics in cancer research and potential clinical impact: a narrative review. Journal of Cancer Research and Clinical Oncology, 150(6), 296-1-296-16. DOI Scopus15 WoS14 Europe PMC14
2022	Cilento, M. A., Klein, O., Egan, E., & Roberts‐Thomson, R. (2022). Talimogene laherparepvec resulting in near‐complete response in a patient with treatment‐refractory Merkel cell carcinoma. Australasian Journal of Dermatology, 63(3), e222-e225. DOI Scopus9 WoS8 Europe PMC6
2022	Cilento, M. A., Kim, C., Chang, S., Farshid, G., & Brown, M. P. (2022). Three cases of BRAF-mutant melanoma with divergent differentiation masquerading as sarcoma.. Pathologica, 114(3), 217-220. DOI Scopus7 WoS7 Europe PMC5
2021	Cilento, M. A., & Hocking, C. M. (2021). Cystic and cavitating lung lesions as a presenting finding of metastatic prostate cancer. Medical Journal of Australia, 214(10), 459-459.e1. DOI Scopus2 WoS1 Europe PMC1
2021	Cilento, M. A., Poplawski, N. K., Paramasivam, S., Thomas, D. M., & Kichenadasse, G. (2021). Germline PALB2 variants and PARP inhibitors in endometrial cancer. Jnccn Journal of the National Comprehensive Cancer Network, 19(11), 1212-1217. DOI Scopus8 WoS7 Europe PMC8

Conference Items

Year	Citation
2023	Cilento, M. A., Mah, C. Y., Martelotto, L., Sweeney, C. J., & Butler, L. M. (2023). Multiomic analysis workflow for biomarker discovery in human prostate cancer. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
2022	Cilento, M. A., Chalwin, R., Hocking, C., Chan, L., Smithers, L., & Joshi, R. (2022). MORBIDITY AND MORTALITY OF ONCOLOGY PATIENTS ADMITTED TO AN INTENSIVE CARE UNIT. Poster session presented at the meeting of INTERNAL MEDICINE JOURNAL. WILEY.
2021	Cilento, M., & Roberts-Thomson, R. (2021). Weight changes during adjuvant nivolumab for resected melanoma. Poster session presented at the meeting of Poster Abstracts. Asia-Pacific Journal of Clinical Oncology, 17: 110-208.. Virtual. DOI

Email: michael.cilento@adelaide.edu.au

Michael Cilento

Journals

Conference Items

Connect With Me

External Profiles